These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23599364)

  • 1. Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.
    McCarthy M
    BMJ; 2013 Apr; 346():f2499. PubMed ID: 23599364
    [No Abstract]   [Full Text] [Related]  

  • 2. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
    Olevsky OM; Martino S
    Menopause; 2008; 15(4 Suppl):790-6. PubMed ID: 18596600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experts add second drug to breast cancer prevention regimen.
    Harv Womens Health Watch; 2013 Oct; 21(2):8. PubMed ID: 24432457
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exemestane is effective for the chemoprevention of breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(6):363-4. PubMed ID: 21898372
    [No Abstract]   [Full Text] [Related]  

  • 8. [From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].
    Kreienberg R; Kafka A
    MMW Fortschr Med; 2003 Jun; 145(24):32-3. PubMed ID: 12866296
    [No Abstract]   [Full Text] [Related]  

  • 9. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs can reduce the incidence of breast cancer: now what?
    Wozniak TF; Eppes PG; Wilson CT
    Del Med J; 1999 Sep; 71(9):387-9. PubMed ID: 10584440
    [No Abstract]   [Full Text] [Related]  

  • 12. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
    Harv Womens Health Watch; 2002 Oct; 10(2):1-2. PubMed ID: 12393316
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.
    Vogel VG
    Menopause; 2009; 16(6):1079-82. PubMed ID: 19779314
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current perspective of chemoprevention in breast cancer].
    Asaga S; Jinno H; Sakata M; Kitajima M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():627-32. PubMed ID: 17682221
    [No Abstract]   [Full Text] [Related]  

  • 16. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
    Fabian C
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
    [No Abstract]   [Full Text] [Related]  

  • 17. Independent assessment supports a role for tamoxifen in breast cancer risk reduction.
    Oncology (Williston Park); 1999 Sep; 13(9):1211. PubMed ID: 10509317
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population.
    Noah-Vanhoucke J; Green LE; Dinh TA; Alperin P; Smith RA
    Cancer; 2011 Aug; 117(15):3322-31. PubMed ID: 21404271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
    Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.